Skip to main content

FDA Updates

Keytruda Received FDA Approval for Adjuvant Treatment of Non–Small-Cell Lung Cancer

Tukysa, in Combination with Trastuzumab, Now FDA Approved for HER2-Positive Unresectable or Metastatic Colorectal Cancer

Brukinsa Now FDA Approved for Patients with CLL or SLL

Tecentriq Now FDA Approved for Treatment of Alveolar Soft-Part Sarcoma

Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer

Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation

Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma

Imjudo, a New CTLA-4 Inhibitor FDA Approved in Combination with Imfinzi for Unresectable Hepatocellular Carcinoma

Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic Non–Small-Cell Lung Cancer

Rylaze Received FDA Approval of a New Dosing Regimen

2
3
4
5
6
7
8

Page 5 of 33
Results 41 - 50 of 330